Drug Acceleration Experts Launch New Biotech Startup With Eye on Cancer Treatments, Global Partnerships for Patients
Retrieved on:
Thursday, March 17, 2022
Clinical professor, Drug development, Method, Organization, Cancer, Plasma protein binding, Therapy, DRS, Research, Doctor of Philosophy, Death, CEO, Thought, Communication, MD, LLC, Mayo Clinic, Safety, Entrepreneurship, Acceleration, Solution, Pancreatic cancer, Patient, Partnership, Pharmaceutical industry, Lamassu
DURHAM, N.C., March 17, 2022 /PRNewswire/ -- The team of entrepreneur physician-scientists who first developed the novel therapeutic RABI-767 for the treatment of severe acute pancreatitis have launched a new biotech startup to accelerate the development of novel therapeutics for major unmet needs and difficult-to-treat diseases. The startup, Lamassu Bio, Inc., will first focus its research efforts on the development of novel therapeutics for the treatment of multiple cancers, including pancreatic cancer.
Key Points:
- The startup, Lamassu Bio, Inc., will first focus its research efforts on the development of novel therapeutics for the treatment of multiple cancers, including pancreatic cancer.
- These new partnerships will allow scientists to utilize global research knowledge and expertise to accelerate the development and commercialization of therapeutics.
- "We believe our methods, which have already proven successful in the United States, can benefit patients worldwide.
- Rabi Hanna, MD and Greg Palmer, PhD, founded Lamassu Pharma, LLC, a biotech startup, in partnership with the Mayo Clinic.